SCHEMBL6435303

SCHEMBL6435303

O=C(O)c1cccc(C=NNc2nc3nonc3nc2Nc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.48
CBS P35520 1/20 0.42
MAPT P10636 12/20 0.41
NPC1 O15118 12/20 0.41
RAB9A P51151 12/20 0.41
GAA P10253 10/20 0.41
SMN1; SMN2 Q16637 9/20 0.41
TP53 P04637 2/20 0.41
CCR2 P41597 1/20 0.41
CCR5 P51681 1/20 0.41
KMT2A Q03164 11/20 0.40
ALDH1A1 P00352 6/20 0.40
HSP90AA1 P07900 1/20 0.40
MEN1 O00255 10/20 0.39
KDM4E B2RXH2 2/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
POLB P06746 4/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415698 0.92 NPC1 (0.47) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6415963 0.88 BIRC5 (0.52) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6412970 0.86 MAPT (0.46) MAPTNPC1RAB9AGAASMN1; SMN2
SCHEMBL6419742 0.84 BIRC5 (0.69) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6419739 0.84 BIRC5 (0.69) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6417027 0.81 TDP1 (0.47) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6432172 0.81 GAA (0.47) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6431849 0.81 RAB9A (0.49) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6414740 0.79 BIRC5 (0.57) BIRC5MAPTNPC1RAB9AGAA
SCHEMBL6414735 0.79 BIRC5 (0.57) BIRC5MAPTNPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885CBS 4589/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.